The State of Biotech

Close to the Edge

Perfect Pitch: Genome Editing Pioneer Fyodor Urnov on Commercializing CRISPR Therapies and Epigenomic Tuning

BIO CEO Rachel King Outlines Industry’s Challenges on “Close to the Edge”

Carl Icahn States His Case for Change at Illumina on “Close to the Edge”

Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge”

Decoding Genomic Diversity with deCODE Genetics CEO Kári Stefánsson on “Close to the Edge”

Front Row

GEN Edge Live